GSK adds Royal Philips' Chief Executive Jakobs to board
(Alliance News) - GSK PLC on Thursday announced that Roy Jakobs, the chief executive officer of Royal Philips NV, will join its board next week as a non-executive director. Read More
| Price | 1,960.00p on 09-07-2026 at 12:01:02 |
|---|---|
| Change | -19.50p -0.99% |
| Buy | 1,960.50p |
| Sell | 1,960.00p |
| Last Trade: | Unknown 0.00 at 1,960.00p |
| Day's Volume: | 2,335,576 |
| Last Close: | 1,979.50p |
| Open: | 1,960.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,951.00p - 1,982.50p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £78.51b |
| VWAP: | 1,963.59023p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 0 | 1,960.00p | SI Trade |
13:01:02 - 09-Jul-26 |
| Unknown* | 0 | 1,960.50p | SI Trade |
13:00:43 - 09-Jul-26 |
| Sell* | 629 | 1,960.00p | Automatic Execution |
13:00:42 - 09-Jul-26 |
| Sell* | 14 | 1,960.00p | Automatic Execution |
13:00:42 - 09-Jul-26 |
| Unknown* | 0 | 1,959.50p | OTC Trade |
13:00:17 - 09-Jul-26 |
| Unknown* | 0 | 1,959.50p | OTC Trade |
13:00:16 - 09-Jul-26 |
| Buy* | 390 | 1,960.00p | Automatic Execution |
13:00:12 - 09-Jul-26 |
| Buy* | 739 | 1,959.762p | Suspected BUY Trade |
13:00:06 - 09-Jul-26 |
| Buy* | 700 | 1,959.50p | Automatic Execution |
13:00:04 - 09-Jul-26 |
| Sell* | 100 | 1,959.50p | Automatic Execution |
13:00:04 - 09-Jul-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 1st Jul 2026 3:00 pm | RNS | Total Voting Rights |
| 29th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 29th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 26th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 24th Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 24th Jun 2026 2:52 pm | RNS | GSK announces tender offer to acquire Nuvalent |
| 23rd Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 22nd Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 17th Jun 2026 4:06 pm | RNS | cUTI oral antibiotic Tebipenem approved by US FDA |
| 15th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |